BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BioCentury | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

...biomarkers Status: Phase IIb discontinued Milestone: NA Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin alpha(4)beta(7) Interleukin-23 (IL-23) receptor...
BioCentury | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

...has Orphan Drug designation in the U.S. Jaime De Leon IL-23 receptor (PTG-200) PTG-100 PTG-300 Johnson & Johnson Protagonist Therapeutics Inc. Integrin alpha(4)beta(7) Interleukin-23 (IL-23) receptor...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...antagonist, in Phase I testing to treat Crohn’s disease and inflammatory bowel disease (IBD). TARGET/MARKER/PATHWAY: Interleukin-23 receptor...
...doi:10.1126/scitranslmed.aal1571 CONTACT: Giovanna Cutrona, San Martino University Hospital, Genoa, Italy email: giovanna.cutrona@hsanmartino.it Hongjiang Li San Martino University Hospital Interleukin-23 (IL-23) receptor Interleukin-23...
BioCentury | Oct 12, 2017
Financial News

Protagonist raises $60M in follow-on

...inflammatory bowel disease (IBD) (see BioCentury Extra, May 30) . Jennie Walters PTG-100 PTG-200 Johnson & Johnson Protagonist Therapeutics Inc. Integrin alpha(4)beta(7) Interleukin-23 (IL-23) receptor...
BioCentury | May 31, 2017
Company News

Protagonist licenses IBD candidate PTG-200 to Janssen

...Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Jaime De Leon PTG-200 Johnson & Johnson Protagonist Therapeutics Inc. Interleukin-23 (IL-23) receptor...
BioCentury | May 30, 2017
Company News

Protagonist soars on Janssen IBD deal

...Extra, July 16, 2015) . Jaime De Leon AMG 139 CNTO 1959 guselkumab MEDI2070 PTG-100 PTG-200 Amgen Inc. Johnson & Johnson Protagonist Therapeutics Inc. Integrin alpha(4)beta(7) Interleukin-23 (IL-23) Interleukin-23 (IL-23) receptor brazikumab Tremfya...
BioCentury | Aug 11, 2016
Top Story

Protagonist raises $90M in bumped-up IPO

...year, it plans to start a Phase I study of PTG-200 , an oral peptide interleukin-23 (IL-23) receptor...
BioCentury | Jul 13, 2016
Financial News

Protagonist files for IPO

...year, it plans to start a Phase I study of PTG-200 , an oral peptide interleukin-23 (IL-23) receptor...
Items per page:
1 - 9 of 9